Zynext Ventures, a Subsidiary of Zydus Lifescience, Invests in Feldan to Advance Cell-Based Drug Delivery

On April 16, 2025, Zynext Ventures USA LLC—the venture capital arm of Zydus Lifesciences—announced its investment in Feldan Therapeutics, a Canadian clinical-stage pharmaceutical company. Feldan focuses on developing new treatments using its special technology that helps deliver medicines directly inside cells.

Innovative Technology to Target Skin and Lung Diseases

Feldan has created a unique “Shuttle peptide” technology. This allows therapeutic molecules to enter cells more effectively and reach their targets. The company’s lead drug, FLD-103, is designed to treat basal cell carcinoma (BCC), a common skin cancer. It’s injected directly into the tumour, where the Shuttle system helps deliver a Hedgehog pathway inhibitor inside cancer cells. The goal is to offer a safer, non-surgical treatment option that improves patients’ quality of life.

Feldan is also working on a lung disease program. It uses the same technology to deliver treatments to hard-to-reach lung cells, helping address the rising need for better respiratory therapies.

Read More Hospital Stocks Like Narayana, HCG, Yatharth Share Price Surge as Demand Rises for Advanced Healthcare. 

Zydus Leaders Support the Vision

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said that the company is committed to advancing innovative treatments that address major gaps in healthcare. He added that the investment will support Feldan in developing safer, targeted therapies for skin and lung conditions.

Jay Kothari, Director at Zynext Ventures, highlighted that Feldan’s platform aligns with Zynext’s mission to invest in breakthrough innovations that can change the future of medicine.

About Zydus Lifesciences

Zydus Lifesciences is a global pharmaceutical company that works to help people live healthier lives. With a team of 27,000 employees—including 1,400 scientists—the company develops and markets a wide range of treatments, including vaccines, biologics, and biosimilars. Zydus is known for launching several first-of-their-kind products in the past decade.

On April 16, 2025, Zydus Lifesciences share price opened at ₹883.15, reached a high of ₹887.25, and touched a low of ₹813.00 during the trading session.

Conclusion

This partnership marks a strategic step toward revolutionising drug delivery by combining Zynext’s vision for innovation with Feldan’s cutting-edge platform. Together, they aim to bring safer, more targeted treatments to patients suffering from skin and lung diseases, improving healthcare outcomes globally.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.    

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.